Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study.

Tapanainen J, Hovatta O, Juntunen K, Martikainen H, Ratsula K, Tulppala M, Tuomivaara L

Human reproduction (Oxford, England)1 Dec 1993Cited by 24 (Europe PMC)

PMID8150902DOI10.1093/oxfordjournals.humrep.a137980PepBankPUB-08150902

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women undergoing IVF stimulation, time for follicular development did not differ between goserelin and buserelin.
In plain wordsIn women undergoing IVF, follicular development time did not differ between goserelin and buserelin.
Peptide
Goserelin
Outcome
No significant changeTime for follicular development
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
There were no differences in the time required for follicular development nor in the clinical outcome between groups treated with either goserelin or buserelin.
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090201
02HumanRandomized controlled trialEfficacy outcome
In women undergoing IVF stimulation, clinical outcome did not differ between goserelin and buserelin.
In plain wordsIn women undergoing IVF, clinical outcome did not differ between goserelin and buserelin.
Peptide
Goserelin
Outcome
No significant changeClinical outcome
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
There were no differences in the time required for follicular development nor in the clinical outcome between groups treated with either goserelin or buserelin.
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090202
03HumanRandomized controlled trialEfficacy outcome
In women undergoing IVF, oocytes recovered averaged 6.7 +/- 5.0 with goserelin versus 6.3 +/- 4.9 with buserelin.
In plain wordsIn women undergoing IVF, oocytes recovered averaged 6.7 with goserelin versus 6.3 with buserelin.
Peptide
Goserelin
Outcome
Not applicableOocytes recovered
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Measurements
Oocytes recovered
6.7 oocytes
goserelin group, SD 5.0
Oocytes recovered
6.3 oocytes
buserelin group, SD 4.9
Source sentences
Summary
The number of oocytes recovered in the goserelin group was 6.7 +/- 5.0 versus 6.3 +/- 4.9 in the buserelin group.
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090203
04HumanRandomized controlled trialEfficacy outcome
In women undergoing IVF, pregnancies occurred in 11 goserelin recipients (22.4%) versus 12 buserelin recipients (24.0%).
In plain wordsIn women undergoing IVF, pregnancy occurred in 22.4% with goserelin versus 24.0% with buserelin.
Peptide
Goserelin
Outcome
Not applicablePregnancy
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Measurements
Pregnancies
11 pregnancies
goserelin group
Pregnancy rate
22.4%
goserelin group
Pregnancies
12 pregnancies
buserelin group
Pregnancy rate
24%
buserelin group
Source sentences
Summary
There were 11 pregnancies after the use of goserelin (22.4%) and 12 pregnancies in those given buserelin (24.0%).
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090204
05HumanRandomized controlled trialEfficacy outcome
In women undergoing IVF, HMG ampoules needed were higher with goserelin than buserelin (27.9 +/- 7.8 versus 24.6 +/- 7.8, P < 0.05).
In plain wordsIn women undergoing IVF, goserelin required more HMG ampoules than buserelin.
Peptide
Goserelin
Outcome
IncreaseHMG ampoules needed
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Measurements
HMG ampoules needed
27.9 ampoules
goserelin group, SD 7.8
HMG ampoules needed
24.6 ampoules
buserelin group, SD 7.8
Source sentences
Summary
The number of HMG ampoules needed for follicular maturation was higher in the goserelin group (27.9 +/- 7.8) than in the buserelin group (24.6 +/- 7.8, P < 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090205
06HumanRandomized controlled trialSafety outcome
In women undergoing IVF, tiredness was significantly less with goserelin than buserelin.
In plain wordsIn women undergoing IVF, tiredness was significantly less with goserelin than buserelin.
Peptide
Goserelin
Outcome
DecreaseTiredness
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Adverse events · Whole body
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
The patients given buserelin suffered significantly more from tiredness, depression, headache and abdominal pain than those receiving goserelin
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090206
07HumanRandomized controlled trialSafety outcome
In women undergoing IVF, depression was significantly less with goserelin than buserelin.
In plain wordsIn women undergoing IVF, depression was significantly less with goserelin than buserelin.
Peptide
Goserelin
Outcome
DecreaseDepression
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Adverse events · Mental health and mood
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
The patients given buserelin suffered significantly more from tiredness, depression, headache and abdominal pain than those receiving goserelin
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090207
08HumanRandomized controlled trialSafety outcome
In women undergoing IVF, headache was significantly less with goserelin than buserelin.
In plain wordsIn women undergoing IVF, headache was significantly less with goserelin than buserelin.
Peptide
Goserelin
Outcome
DecreaseHeadache
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Adverse events · Nervous system and cognition
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
The patients given buserelin suffered significantly more from tiredness, depression, headache and abdominal pain than those receiving goserelin
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090208
09HumanRandomized controlled trialSafety outcome
In women undergoing IVF, abdominal pain was significantly less with goserelin than buserelin.
In plain wordsIn women undergoing IVF, abdominal pain was significantly less with goserelin than buserelin.
Peptide
Goserelin
Outcome
DecreaseAbdominal pain
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
The patients given buserelin suffered significantly more from tiredness, depression, headache and abdominal pain than those receiving goserelin
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090209
10HumanRandomized controlled trialSafety outcome
In women undergoing IVF, mental irritability did not differ between goserelin and buserelin.
In plain wordsIn women undergoing IVF, mental irritability did not differ between goserelin and buserelin.
Peptide
Goserelin
Outcome
No significant changeMental irritability
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Adverse events · Mental health and mood
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
The patients given buserelin suffered significantly more from tiredness, depression, headache and abdominal pain than those receiving goserelin, whereas there were no differences between the groups in experiencing mental irritability, nausea and swelling.
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090210
11HumanRandomized controlled trialSafety outcome
In women undergoing IVF, nausea did not differ between goserelin and buserelin.
In plain wordsIn women undergoing IVF, nausea did not differ between goserelin and buserelin.
Peptide
Goserelin
Outcome
No significant changeNausea
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
The patients given buserelin suffered significantly more from tiredness, depression, headache and abdominal pain than those receiving goserelin, whereas there were no differences between the groups in experiencing mental irritability, nausea and swelling.
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090211
12HumanRandomized controlled trialSafety outcome
In women undergoing IVF, swelling did not differ between goserelin and buserelin.
In plain wordsIn women undergoing IVF, swelling did not differ between goserelin and buserelin.
Peptide
Goserelin
Outcome
No significant changeSwelling
Study
n = 100
Comparator
Intranasal buserelin acetate
Outcome group
Adverse events · Whole body
Studied dose
3.6 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
The patients given buserelin suffered significantly more from tiredness, depression, headache and abdominal pain than those receiving goserelin, whereas there were no differences between the groups in experiencing mental irritability, nausea and swelling.
4 context sentences(design, population, supporting numbers)
Summary · context
One-hundred women undergoing ovarian stimulation with gonadotrophin-releasing hormone agonist (GnRH-a) and a human menopausal gonadotrophin (HMG) for in-vitro fertilization (IVF) participated in this randomized comparative study.
Summary · context
The effectiveness of long-acting s.c. goserelin (Zoladex depot; 49 patients) and intranasally (i.n.) administered buserelin acetate (Suprefact; 51 patients) for pituitary down-regulation was compared.
Summary · context
Treatment with s.c. goserelin (3.6 mg) or i.n. buserelin acetate (200 micrograms; 6 times/day) was started on day 21-23 of the cycle.
Summary · context
Stimulation with 150 IU of HMG/day was started after at least 11 days of GnRH-a treatment.
Report a problemFND-0815090212

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.